FDA-Drug2026-10-16Class IICHEMICAL
Pfizer Levoxyl 175 mcg tablets recalled for subpotent drug strength
What this means
Pfizer is recalling one lot of Levoxyl (levothyroxine sodium) 175 mcg tablets because testing found the tablets contain less active ingredient than specified. This means the medication may not work as intended to treat thyroid conditions. The recall affects lot 24W06 with an expiration date of November 30, 2026.
- Check if your Levoxyl matches lot 24W06 (Exp 11/30/2026); the lot number is on the bottle label.
- Contact your pharmacy or doctor if you have this lot; do not stop taking your medication without guidance.
- Your doctor can confirm whether you need a replacement or dosage adjustment.
The agency's original wording
Hazard
Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
Intended for
Adults
Illnesses reported
None reported
Sold states
US Nationwide and Puerto Rico
Affected count
15,815 100-count bottles
Manufactured in
66 Hudson Blvd, Manhattan, New York, United States
Products
Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01.
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0052-2027More Pfizer recalls
- FDA-Drug2026-10-16Pfizer Levoxyl 175 mcg tablets recalled for subpotent drug content
- FDA-Drug2026-09-23Pfizer Dopamine HCl injection recalled for lack of sterility assurance
Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.